Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.

Cell death & disease - 26 Sept 2013

Chen J, Bi H, Hou J, Zhang X, Zhang C, Yue L, Wen X, Liu D, Shi H, Yuan J, Liu J, Liu B

Abstract excerpt

The exact influence of statins on gefitinib resistance in human non-small cell lung cancer (NSCLC) cells with KRAS mutation alone or KRAS/PIK3CA and KRAS/PTEN comutations remains unclear. This work found that transfection of mutant KRAS plasmids significantly suppressed the gefitinib cytotoxicity in Calu3 cells (wild-type KRAS). Gefitinib disrupted the Kras/PI3K and Kras/Raf complexes in Calu3 cells, whereas not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atorvastatin
Share to Drug Synergism
Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gefitinib

Share to Heptanoic Acids

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Proto-Oncogene Proteins c-raf

Share to Pyrroles

Source

Open in PubMed Open full text

Identifiers

PMID: 24071646
DOI: 10.1038/cddis.2013.312
PMCID: PMC3789171

Genes

KRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.PMID 24071646Read ↗

Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.Semantic proximity Read ↗

Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.Semantic proximity Read ↗

Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation.Semantic proximity Read ↗

The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.Semantic proximity Read ↗

Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.Semantic proximity Read ↗

KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.Semantic proximity Read ↗

Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.Semantic proximity Read ↗

MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathwaySemantic proximity Read ↗

MiR‐133a‐3p attenuates resistance of non‐small cell lung cancer cells to gefitinib by targeting SPAG5Semantic proximity Read ↗

Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation.Semantic proximity Read ↗

MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.Semantic proximity Read ↗

Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.